© The Financial Times Ltd 2016 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Feb 08, 2016, the consensus forecast amongst 34 polled investment analysts covering AstraZeneca plc advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts improved on Jan 20, 2016. The previous consensus forecast advised investors to hold their position in AstraZeneca plc.
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
Share price forecast information is not available for AstraZeneca PLC. View Full Financials
In 2015, AstraZeneca PLC reported a dividend of 2.80 USD, equaling last years dividend. The 29 analysts covering the company expect dividends of 2.75 USD for the upcoming fiscal year, a decrease of 1.71 %. View Full Financials
|Div growth (TTM)||0.00%|
On Feb 04, 2016, AstraZeneca plc reported 4th quarter 2015 earnings of 0.94 per share. This result was in line with the consensus of the 14 analysts following the company and exceeded last year's 4th quarter results by 23.68%.
The next earnings announcement is expected on Apr 29, 2016. View Full Interim Financials
|Average growth rate||+7.58 %|
AstraZeneca plc reported annual 2015 earnings of 4.26 per share on Feb 04, 2016. View Full Annual Financials
|Average growth rate||-12.22 %|
AstraZeneca PLC had 4th quarter 2015 revenues of 6.21bn. This was 7.12 % below the prior year's 4th quarter results. View Full Interim Financials
|Average growth rate||-1.64 %|
AstraZeneca PLC had revenues for the full year 2015 of 23.64bn. This was 9.40 % below the prior year's results. View Full Annual Financials
|Average growth rate||-8.18 %|